Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 4/20 | 0.54 |
| ▸ | MMP9 | P14780 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891433 | 1.00 | MME (0.59) | MMENPSR1CYP1A2NAALAD2FOLH1 | |
| SCHEMBL891432 | 1.00 | MME (0.59) | MMENPSR1CYP1A2NAALAD2FOLH1 | |
| Hydrochloric Acid SCHEMBL5691387 | 0.98 | MME (0.57) | MMENPSR1CYP1A2NAALAD2FOLH1 | |
| Valine SCHEMBL27667759 | 0.85 | SLC1A3 (0.53) | MMEMMP2MMP9L3MBTL1 | |
| SCHEMBL7379335 | 0.85 | MME (0.70) | MMENPSR1CYP1A2NAALAD2FOLH1 | |
| SCHEMBL157547 | 0.85 | MME (0.61) | MMENPSR1CYP1A2NAALAD2FOLH1 | |
| SCHEMBL9068541 | 0.85 | MME (0.70) | MMENPSR1CYP1A2NAALAD2FOLH1 | |
| SCHEMBL156975 | 0.84 | FOLH1 (0.58) | MMENAALAD2FOLH1L3MBTL1 | |
| SCHEMBL156976 | 0.84 | FOLH1 (0.58) | MMENAALAD2FOLH1L3MBTL1 | |
| SCHEMBL1803033 | 0.84 | EPHX1 (0.55) | MMECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193209-A1 | A POLYMER PRODUCT AND PREPARATION THEROF | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2018-07-12 | — | — | US | claimed |
| EP-3319779-A1 | A POLYMER PRODUCT AND PREPARATION THEREOF | Singapore Health Services Pte Ltd (SG) | 2018-05-16 | — | — | EP | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-20230159450-A1 | DIMERS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2023-05-25 | — | — | US | disclosed |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| CN-111836638-A | HLA class I-restricted T cell receptor for mutated RAS | 美国卫生和人力服务部 | 2020-10-27 | — | — | CN | disclosed |
| US-20180193209-A1 | A POLYMER PRODUCT AND PREPARATION THEROF | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2018-07-12 | — | — | US | disclosed |
| EP-3319779-A1 | A POLYMER PRODUCT AND PREPARATION THEREOF | Singapore Health Services Pte Ltd (SG) | 2018-05-16 | — | — | EP | disclosed |
| CN-101084248-A | Macroporous plastic bead material | ROEHM GMBH (DE) | 2007-12-05 | — | — | CN | disclosed |
| EP-0330247-B1 | N-HYDROXY-ALPHA-AMINO ACIDS, AMIDES AND OTHER DERIVATIVES THEREOF | DSM N.V. (NL) | 1993-07-07 | — | — | EP | disclosed |
| US-5101036-A | PROCESS FOR THE PREPARATION OF N-HYDROXY-ALPHA-AMINO ACID AMIDES | STAMICARBON B.V. (NL) | 1992-03-31 | — | — | US | disclosed |
| US-5072041-A | OPTICALLY ACTIVE N-HYDROXY-ALPHA-AMINO ACIDS, AMIDES AND THEIR DERIVATIVES | STAMICARBON B.V. (NL) | 1991-12-10 | — | — | US | disclosed |
| EP-0330247-A1 | N-hydroxy-alpha-amino acids, amides and other derivatives thereof | DSM N.V. (NL) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | MME 3022/4885NPSR1 139/4885CYP1A2 4402/4885 |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | MDM2, TP53, TP53BP1 | MME 1213/4885NPSR1 2708/4885CYP1A2 4431/4885 |
| US-20230159450-A1 | DIMERS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | DNPEP, DAP3, ANPEP | MME 828/4885NPSR1 80/4885CYP1A2 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.